Sec. 4001. SHORT TITLE; FINDING

145 words·~1 min read·/statute-compilations/comps-17191/sec-4001

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

## SEC. 4001 SHORT TITLE; FINDING ###

(a)Short Title **[**[21 U.S.C. 301 note](/us/usc/t21/s301)**]** This title may be cited as the “Biosimilar User Fee Amendments of 2022”. ###

(b)Finding **[**[21 U.S.C. 379j-51 note](/us/usc/t21/s379j-51)**]** Congress finds that the fees authorized by the amendments made by this title will be dedicated to expediting the process for the review of biosimilar biological product applications, including postmarket safety activities, as set forth in the goals identified for purposes of part 8 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j-51 et seq.), in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record.

Connectionstraces to 2

Traces to 2 documents

U.S. Code

Citation graph

cites case law

Sec. 4001

SHORT TITLE; FINDING

U.S.C.§ 301

U.S.C.§ 379j–51

Cites 2Cited by 0 across 0 sources